$PropNex(OYY.SI)$ The strong sales at Emerald of Katong, Chuan Park, Nava Grove will contribute to healthy revenue for PropNex over the next two quarter (there is a lag in commission proceeds). The resale market has also been resilient in 2024 with strong transaction volume. A number of upcoming large developments in 2025 like Elta, The Orie and Parktown Residence will likely also draw strong demand that will support PropNex's revenue and share price growth.
Think the Fed will likely postpone any rate cuts to next year. Loosening any earlier risks negating all their effort over the past 2 years to contain inflation. Economy seems to be in decent condition and unemployment rate remains low. Little reason to cut early.
$Trillium Therapeutics(TRIL)$operating planis on track. Focus is on strong executionto ensure a robust flow of new data starting in 4Q 2021 and 2022. Holding $265m cash position. Trillium’s position as a leading CD47 company makes it a buy at $6.10
$Myovant Sciences Ltd.(MYOV)$ Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc) https://s.flashalert.me/IPr3X
$Jumia Technologies AG(JMIA)$Huawei has announced a partnership with Africa’s e-commerce leader Jumia. The partnership will enable customers searching for products on the Petal Search shopping channel to conveniently click through to the Jumia product page and buy instantly